Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cutera, Inc. stock logo
CUTR
Cutera
$0.04
-63.9%
$0.04
$0.09
$1.87
$787K1.362.78 million shs27.70 million shs
NeurAxis, Inc. stock logo
NRXS
NeurAxis
$2.56
+6.2%
$2.53
$1.33
$6.20
$18.47M3.09420,430 shs134,058 shs
ViewRay, Inc. stock logo
VRAY
ViewRay
$0.34
$0.02
$4.96
$4.59M0.817.51 million shs108.50 million shs
VRAYQ
ViewRay
$0.00
$0.00
$0.00
$18K1.02600 shs883 shs
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cutera, Inc. stock logo
CUTR
Cutera
0.00%0.00%0.00%0.00%-96.98%
NeurAxis, Inc. stock logo
NRXS
NeurAxis
+6.22%+1.59%-7.58%+38.38%-10.49%
ViewRay, Inc. stock logo
VRAY
ViewRay
0.00%0.00%0.00%0.00%0.00%
VRAYQ
ViewRay
0.00%-2.91%-2.91%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cutera, Inc. stock logo
CUTR
Cutera
N/AN/AN/AN/AN/AN/AN/AN/A
NeurAxis, Inc. stock logo
NRXS
NeurAxis
3.5029 of 5 stars
3.55.00.00.02.63.30.0
ViewRay, Inc. stock logo
VRAY
ViewRay
N/AN/AN/AN/AN/AN/AN/AN/A
VRAYQ
ViewRay
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cutera, Inc. stock logo
CUTR
Cutera
2.50
Moderate Buy$3.007,592.31% Upside
NeurAxis, Inc. stock logo
NRXS
NeurAxis
3.00
Buy$7.00173.44% Upside
ViewRay, Inc. stock logo
VRAY
ViewRay
0.00
N/AN/AN/A
VRAYQ
ViewRay
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest VRAY, NRXS, CUTR, and VRAYQ Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/16/2025
NeurAxis, Inc. stock logo
NRXS
NeurAxis
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
6/16/2025
NeurAxis, Inc. stock logo
NRXS
NeurAxis
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$7.00
(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cutera, Inc. stock logo
CUTR
Cutera
$155.21M0.01N/AN/A($8.62) per share0.00
NeurAxis, Inc. stock logo
NRXS
NeurAxis
$2.93M6.29N/AN/A($0.27) per share-9.48
ViewRay, Inc. stock logo
VRAY
ViewRay
$105.86M0.00N/AN/A$0.45 per share0.00
VRAYQ
ViewRay
$102.21M0.00N/AN/AN/ANaN
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cutera, Inc. stock logo
CUTR
Cutera
-$162.83M-$6.58N/AN/AN/A-84.86%N/A-45.07%8/6/2025 (Estimated)
NeurAxis, Inc. stock logo
NRXS
NeurAxis
-$14.63M-$1.19N/AN/A-492.76%N/A-641.25%N/A
ViewRay, Inc. stock logo
VRAY
ViewRay
-$107.33M-$0.60N/AN/AN/A-104.30%-120.48%-42.39%N/A
VRAYQ
ViewRay
-$107.33MN/A0.00N/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cutera, Inc. stock logo
CUTR
Cutera
N/AN/AN/AN/AN/A
NeurAxis, Inc. stock logo
NRXS
NeurAxis
N/AN/AN/AN/AN/A
ViewRay, Inc. stock logo
VRAY
ViewRay
N/AN/AN/AN/AN/A
VRAYQ
ViewRay
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cutera, Inc. stock logo
CUTR
Cutera
N/A
2.88
1.86
NeurAxis, Inc. stock logo
NRXS
NeurAxis
N/A
0.24
0.23
ViewRay, Inc. stock logo
VRAY
ViewRay
N/A
1.16
0.91
VRAYQ
ViewRay
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Cutera, Inc. stock logo
CUTR
Cutera
90.70%
NeurAxis, Inc. stock logo
NRXS
NeurAxis
11.77%
ViewRay, Inc. stock logo
VRAY
ViewRay
92.97%
VRAYQ
ViewRay
15.47%

Insider Ownership

CompanyInsider Ownership
Cutera, Inc. stock logo
CUTR
Cutera
0.42%
NeurAxis, Inc. stock logo
NRXS
NeurAxis
26.40%
ViewRay, Inc. stock logo
VRAY
ViewRay
2.50%
VRAYQ
ViewRay
2.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cutera, Inc. stock logo
CUTR
Cutera
46020.19 million20.10 millionOptionable
NeurAxis, Inc. stock logo
NRXS
NeurAxis
197.22 million6.09 millionNot Optionable
ViewRay, Inc. stock logo
VRAY
ViewRay
295183.40 million178.82 millionOptionable
VRAYQ
ViewRay
300183.40 million178.82 millionNo Data

Recent News About These Companies

No headlines for this company have been tracked by MarketBeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cutera stock logo

Cutera NASDAQ:CUTR

$0.04 -0.07 (-63.86%)
Closing price 03/12/2025
Extended Trading
$0.04 0.00 (0.00%)
As of 03/12/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cutera, Inc. provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designs to strengthen, firm and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform. It also offers truSculpt, a high-powered radio frequency system designed for circumferential reduction, lipolysis, and deep tissue heating and treat all skin types; Secret RF, a fractional RF microneedling device that delivers heat into the deeper layers of the skin using controlled RF energy; and Enlighten SR/III, a laser platform with a dual wavelength for multi-colored tattoo removal, and the treatment of benign pigmented lesions and acne scars. In addition, the company provides Excel HR, a hair removal solution for all skin types; xeo, a multi-application platform for the removal of unwanted hair, treatment of vascular lesions, and skin revitalization by treating discoloration, fine lines, and laxity; and Secret DUO, two dual non-ablative fractional technologies that can be used individually or in combination to target a variety of aesthetic concerns and skin conditions on all skin types with little to no downtime. Further, it offers its products through direct sales and services, and network of distributors and direct international sales. Cutera, Inc. was incorporated in 1998 and is headquartered in Brisbane, California.

NeurAxis stock logo

NeurAxis NASDAQ:NRXS

$2.56 +0.15 (+6.22%)
Closing price 07/3/2025 03:46 PM Eastern
Extended Trading
$2.58 +0.02 (+0.59%)
As of 07/3/2025 04:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.

ViewRay stock logo

ViewRay NASDAQ:VRAY

ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, Italy, France, Taiwan, the United Kingdom, and internationally. It provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers through a network of direct sales force and distributors. ViewRay, Inc. was founded in 2004 and is headquartered in Denver, Colorado.

ViewRay NASDAQ:VRAYQ

ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, Italy, France, Taiwan, the United Kingdom, and internationally. It provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers through a network of direct sales force and distributors. ViewRay, Inc. was founded in 2004 and is headquartered in Denver, Colorado. On July 16, 2023, ViewRay, Inc., alongwith its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. On October 26, 2023, the voluntary petition of ViewRay , Inc. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on July 16, 2023.